CY1113870T1 - Φαρμακοτεχνικες μορφες για την απελευθερωση δραστικων ενωσεων - Google Patents

Φαρμακοτεχνικες μορφες για την απελευθερωση δραστικων ενωσεων

Info

Publication number
CY1113870T1
CY1113870T1 CY20131100274T CY131100274T CY1113870T1 CY 1113870 T1 CY1113870 T1 CY 1113870T1 CY 20131100274 T CY20131100274 T CY 20131100274T CY 131100274 T CY131100274 T CY 131100274T CY 1113870 T1 CY1113870 T1 CY 1113870T1
Authority
CY
Cyprus
Prior art keywords
release
active compounds
pharmaceutical forms
formulation
polymeric matrix
Prior art date
Application number
CY20131100274T
Other languages
English (en)
Inventor
Encina Iván López-Belmonte
Aduriz Ibon Gutierro
Original Assignee
Laboratorios Farmacéuticos Rovi, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Farmacéuticos Rovi, S.A. filed Critical Laboratorios Farmacéuticos Rovi, S.A.
Publication of CY1113870T1 publication Critical patent/CY1113870T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Φαρμακοτεχνική μορφή που περιέχει τουλάχιστον μία δραστική ένωση και πολυμερική μήτρα, όπου η εν λόγω πολυμερική μήτρα περιλαμβάνει τουλάχιστον ένα κατιονικό πολυμερές, διαδικασία παρασκευής της εν λόγω φαρμακοτεχνικής μορφής, φαρμακευτικό παρασκεύασμα που περιλαμβάνει την εν λόγω φαρμακοτεχνική μορφή, οι χρήσεις τους για την παρασκευή ενός φαρμάκου και μια θεραπευτική μέθοδος με χρήση των φαρμακοτεχνικών μορφών και των παρασκευασμάτων.
CY20131100274T 2007-11-14 2013-04-02 Φαρμακοτεχνικες μορφες για την απελευθερωση δραστικων ενωσεων CY1113870T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07380319A EP2060253A1 (en) 2007-11-14 2007-11-14 Pharmaceutical forms for the release of active compounds
EP08850798A EP2219611B1 (en) 2007-11-14 2008-11-13 Pharmaceutical forms for the release of active compounds

Publications (1)

Publication Number Publication Date
CY1113870T1 true CY1113870T1 (el) 2016-07-27

Family

ID=39259537

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100274T CY1113870T1 (el) 2007-11-14 2013-04-02 Φαρμακοτεχνικες μορφες για την απελευθερωση δραστικων ενωσεων

Country Status (8)

Country Link
EP (2) EP2060253A1 (el)
CY (1) CY1113870T1 (el)
DK (1) DK2219611T3 (el)
ES (1) ES2401940T3 (el)
PL (1) PL2219611T3 (el)
PT (1) PT2219611E (el)
SI (1) SI2219611T1 (el)
WO (1) WO2009063021A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101864465B1 (ko) 2014-01-21 2018-06-04 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 의료용 도관을 통한 생체 내 투여성 마이크로 입자

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6475493B1 (en) 1999-09-02 2002-11-05 Norstrum Pharmaceuticals, Inc. Controlled release pellet formulation
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
ITMI20012599A1 (it) 2001-12-11 2003-06-11 Cosmo Spa Composizioni farmaceutiche per la somministrazione orale di eparina osuoi derivati, utili per la terapia di malattie infiammatorie dell'int
DE10260921A1 (de) 2002-12-20 2004-07-01 Röhm GmbH & Co. KG Verfahren zum Überziehen von Substraten für pharmazeutische Anwendungen mit einem Gemisch aus zwei filmbildenden Überzugsmitteln
ES2222822B1 (es) 2003-07-28 2005-12-16 Laboratorios Farmaceuticos Rovi, S.A. Diamidas de aminoacidos en posicion no alfa utiles como adyuvantes para la administracion de agentes biologicos activos.
JP2007507339A (ja) * 2003-10-01 2007-03-29 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム 粒子製造装置及び方法
WO2006023207A2 (en) 2004-08-19 2006-03-02 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Coacervate of anionic and cationic polymer forming microparticles for the sustained release of therapeutic agents
WO2007021970A2 (en) 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Stable pharmaceutical formulations and methods of use thereof

Also Published As

Publication number Publication date
PT2219611E (pt) 2013-03-27
EP2219611B1 (en) 2013-01-09
WO2009063021A1 (en) 2009-05-22
SI2219611T1 (sl) 2013-07-31
ES2401940T3 (es) 2013-04-25
EP2060253A1 (en) 2009-05-20
EP2219611A1 (en) 2010-08-25
PL2219611T3 (pl) 2013-07-31
DK2219611T3 (da) 2013-04-02

Similar Documents

Publication Publication Date Title
CY1123162T1 (el) Ελεγχομενης αποδεσμευσης φαρμακευτικα σκευασματα νιταζοξανιδης
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
CY1111389T1 (el) Φαρμακευτικες ενωσεις που περιεχουν ιματινιμπη και ενα επιβραδυντικο εκλυσης
CY1118731T1 (el) Φαρμακευτικες συνθεσεις αλβιγλουτιδης
AR033423A1 (es) Sales farmaceuticas constituidas de una sustancia activa farmaceutica y al menos un edulcorante, medicamentos que contienen estas sales y uso de estas sales para la preparacion de medicamentos
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CY1116927T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
CY1113003T1 (el) Ευσταθη παρασκευασματα laquinimod
GT200500307A (es) Compuestos quimicos
UY30759A1 (es) Compuestos quimicos
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
CL2008003789A1 (es) Compuestos derivados de bencimidazol sustituido por carboxilo o por hidroxilo, moduladores selectivos del receptor x de farnesoide (fxr); proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, dislipidemia, sindrome metabolico, cancer, alzheimer.
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
UY31975A (es) Sistema y administración transdérmica de estrógeno
CY1114311T1 (el) Θεραπευτικα συστηματα αμεσης απελευθερωσης για βελτιωμενη απο του στοματος απορροφηση 7-[(ε)-τριτ-βουτυλοξυιμινομεθυλο]καμπτοθεκινης
UY30544A1 (es) Compuestos de pirrolo-piperidina y sales farmacéuticametne aceptables de los mismos, procesos de fabricacion, composiciones y aplicaciones
CL2008002479A1 (es) Composicion farmaceutica que comprende: a) una o mas sustancias medicamentosas, b) un lipido, c) un co-lipido y d) un mejorador de flujo; formulacion en polvo seco; procesos de elaboracion.
WO2007090661A3 (en) Active substance combination comprising azolylcarbinol compounds
BRPI0607413A2 (pt) composição farmacêutica compreendendo derivados de indolilmaleimida
BRPI0518790A2 (pt) formulaÇço farmacÊutica, processo para preparar uma formulaÇço farmacÊutica, produto, e, cÁpsula ou tablete